FIELD: chemistry.
SUBSTANCE: invention refers to compounds of formula (I) or its pharmaceutically acceptable salt where radicals R1, R2, n1 and n2, Y and X are valued in the description, R3 stands for heterocyclic group of corollary formula (bb) 
(specified below). These compounds are phosphodiesterase (PDE) inhibitors, particularly PDE4 inhibitors. There is also disclosed production process of pharmaceutical compositions containing compound of formula 
or its pharmaceutically acceptable salt as an active component, and their application in manufacturing of a medicine for treatment and/or prevention of inflammatory and/or allergic disease in mammals, including humans, e.g. asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, allergic rhinitis, rheumatoid arthritis, disseminated sclerosis, Alzheimer's disease, depression or pain in mammals, including humans.
EFFECT: higher effectiveness of the composition and medication therapy.
20 cl, 686 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRASOLE[3,4-b]PYRIDINE COMPOUNDS AND THEIR APPLICATION AS PHOSPHODIESTERASE INHIBITORS | 2003 |
|
RU2348633C2 |
| DERIVATIVES OF AZAINDASOLE OR DIAZAINDASOLE TYPE FOR PAIN TREATMENT | 2013 |
|
RU2640046C2 |
| DERIVATIVE OF THIENOPYRAZOLE, HAVING ACTIVITY THAT INHIBITS PHOSPHODIESTERASE 7(PDE 7) | 2005 |
|
RU2376309C2 |
| AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS MEDICINE | 2012 |
|
RU2600976C2 |
| SERIN / TREONIN KINASE INHIBITORS FOR TREATING OF HYPEROPLIFERATIVE DISEASES | 2013 |
|
RU2644947C2 |
| SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
| METHODS OF OBTAINING AND PURIFICATION OF HETEROARYL COMPOUNDS | 2010 |
|
RU2557242C2 |
| COMPOUNDS OF PYRIDAZINAMIDE AND THEIR USE AS SYNTHETIC SYNECKINASIS INHIBITORS (SYK) | 2013 |
|
RU2627661C2 |
| AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
| CONDENSED TRIAZOLAMINES AS P2X7 MODULATORS | 2010 |
|
RU2533122C2 |
